240 related articles for article (PubMed ID: 20827186)
1. Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation.
Hansen JA; Chien JW; Warren EH; Zhao LP; Martin PJ
Curr Opin Hematol; 2010 Nov; 17(6):483-92. PubMed ID: 20827186
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease.
Martin PJ; Levine DM; Storer BE; Warren EH; Zheng X; Nelson SC; Smith AG; Mortensen BK; Hansen JA
Blood; 2017 Feb; 129(6):791-798. PubMed ID: 27872059
[TBL] [Abstract][Full Text] [Related]
4. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
5. Multiple functional variants in the
Karaesmen E; Hahn T; Dile AJ; Rizvi AA; Wang J; Wang T; Haagenson MD; Preus L; Zhu Q; Liu Q; Yan L; Liu S; Haiman CA; Stram D; Pooler L; Sheng X; Van Den Berg D; Brock G; Webb A; McCarthy PL; Pasquini MC; Spellman SR; Lee SJ; Paczesny S; Sucheston-Campbell LE
Blood Adv; 2019 Aug; 3(16):2512-2524. PubMed ID: 31455667
[TBL] [Abstract][Full Text] [Related]
6. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
7. Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation.
Partanen J; Hyvärinen K; Bickeböller H; Bogunia-Kubik K; Crossland RE; Ivanova M; Perutelli F; Dressel R
Front Immunol; 2020; 11():575492. PubMed ID: 33193367
[TBL] [Abstract][Full Text] [Related]
8. Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant.
Wang W; Huang H; Halagan M; Vierra-Green C; Heuer M; Brelsford JE; Haagenson M; Scheuermann RH; Telenti A; Biggs W; Pearson NM; Udell J; Spellman S; Maiers M; Kennedy CJ
Blood Adv; 2018 Oct; 2(19):2419-2429. PubMed ID: 30262602
[TBL] [Abstract][Full Text] [Related]
9. [Evidence of GVHD/GVL in allogeneic hematopoietic stem cell transplantation from sex-mismatched donors].
Nakasone H
Rinsho Ketsueki; 2024; 65(4):265-271. PubMed ID: 38684437
[TBL] [Abstract][Full Text] [Related]
10. Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation.
Petersdorf EW; Malkki M; Horowitz MM; Spellman SR; Haagenson MD; Wang T
Blood; 2013 Mar; 121(10):1896-905. PubMed ID: 23305741
[TBL] [Abstract][Full Text] [Related]
11. Association of recipient and donor interleukin 6 polymorphisms 174 and 597 with outcome after allogeneic hematopoietic stem cell transplantation in children.
Wetzel L; Wittig S; Gruhn B
J Cancer Res Clin Oncol; 2022 Jan; 148(1):255-265. PubMed ID: 34120222
[TBL] [Abstract][Full Text] [Related]
12. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.
Weisdorf DJ; Nelson G; Lee SJ; Haagenson M; Spellman S; Antin JH; Bolwell B; Cahn JY; Cervantes F; Copelan E; Gale R; Gratwohl A; Khoury HJ; McCarthy P; Marks DI; Szer J; Woolfrey A; Cortes-Franco J; Horowitz MM; Arora M;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1475-8. PubMed ID: 19822308
[TBL] [Abstract][Full Text] [Related]
13. Association of polymorphic MHC microsatellites with GVHD, survival, and leukemia relapse in unrelated hematopoietic stem cell transplant donor/recipient pairs matched at five HLA loci.
Li S; Kawata H; Katsuyama Y; Ota M; Morishima Y; Mano S; Kulski JK; Naruse T; Inoko H
Tissue Antigens; 2004 Apr; 63(4):362-8. PubMed ID: 15009808
[TBL] [Abstract][Full Text] [Related]
14. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
[TBL] [Abstract][Full Text] [Related]
15. How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?
Aizawa K; Peltier D; Matsuki E; Toubai T
Transfus Apher Sci; 2022 Apr; 61(2):103405. PubMed ID: 35210194
[TBL] [Abstract][Full Text] [Related]
16. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Socié G; Loiseau P; Tamouza R; Janin A; Busson M; Gluckman E; Charron D
Transplantation; 2001 Aug; 72(4):699-706. PubMed ID: 11544434
[TBL] [Abstract][Full Text] [Related]
17. A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation.
Martin PJ; Levine DM; Storer BE; Zheng X; Jain D; Heavner B; Norris BM; Geraghty DE; Spellman SR; Sather CL; Wu F; Hansen JA
Front Immunol; 2021; 12():782152. PubMed ID: 34868058
[TBL] [Abstract][Full Text] [Related]
18. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
[TBL] [Abstract][Full Text] [Related]
19. Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT.
Warren EH; Zhang XC; Li S; Fan W; Storer BE; Chien JW; Boeckh MJ; Zhao LP; Martin PJ; Hansen JA
Blood; 2012 Oct; 120(14):2796-806. PubMed ID: 22859606
[TBL] [Abstract][Full Text] [Related]
20. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
